Amphotericin B use in children: Conventional and lipid-based formulations

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 3, 2011, Pages 357-367

  Kuyucu, Necdet ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

amphotericin B; antifungal treatment; Aspergillus infections; Candida infections; fungal infections; pediatric

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POSACONAZOLE; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; BRONCHOSPASM; CANDIDIASIS; CHILL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIMORPHIC FUNGAL INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; RESPIRATORY DISTRESS; REVIEW; RIGOR; SYSTEMIC MYCOSIS; THROMBOPHLEBITIS; VOMITING; ZYGOMYCOSIS;

EID: 79952948917     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.5     Document Type: Review

References (121)

1. Drew RH. Polyenes for prevention and treatment of invasive fungal infections. In:Antifungal Therapy. Ghannoum MA, Perfect JR (Eds). New York Infarma Healthcare, USA, 163-183 (2010).
2. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308-329 (1990). (Pubitemid 20118658)
3. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30, 710-718 (2000).
4. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45, 807-825 (2007). (Pubitemid 47580372)
5. Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 1801-1812 (2008).
6. Kauffman CA, Bustamante B, Chapman SW et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45, 1255-1265 (2007). (Pubitemid 351411897)
7. Kanafani ZA, Perfect JR. Resistance to antifungal agents: Mechanisms and clinical impact. Clin. Infect. Dis. 46, 120-128 (2008). (Pubitemid 351263573)
8. Roilides E, Lyman CA, Filioti J et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46, 1974-1976 (2002). (Pubitemid 34535224)
9. Douglas S. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 19, 306-323 (1999).
10. Abuhammour W, Habte-Gaber E. Newer antifungal agents. Indian J. Pediatr. 71, 253-259 (2004). (Pubitemid 38436964)
11. Lewis RE, Wiederhold NP, Prince RA et al. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J. Antimicrob. Chemother. 57, 288-293 (2006). (Pubitemid 43160171)
12. Lewis RE, Wiederhold NP, Klepser ME et al. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob. Agents Chemother. 49, 945-951 (2005). (Pubitemid 40327708)
13. Ernst EJ, Klepser ME, Pfaller MA et al. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44, 1108-1111 (2000). (Pubitemid 30165304)
14. Rogers PD, Pearson MM, Cleary JD et al. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother. 50, 811-817 (2002). (Pubitemid 36032799)
15. Sau K, Mambula SS, Latz E et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568 (2003). (Pubitemid 37175278)
16. Ben Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: Immunopharmacology of modern antifungals. Clin. Infect. Dis. 47, 226-235 (2008). (Pubitemid 351952889)
17. Gigliotti F, Shenep JL, Lott L et al. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. 156, 784-789 (1987). (Pubitemid 17157429)
18. Andes D, Stamsted T, Conklin R et al. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminatedcandidiasis model. Antimicrob. Agents Chemother. 45(3), 922-926 (2001). (Pubitemid 32182046)
19. Vitale RG, Meis JF, Mouton JW et al. Evaluation of the post-antifungal effect [PAFE] of amphotericin B and nystatin against 30 Zygomycetes using two different media. J. Antimicrob. Chemother. 52, 65-70 (2003). (Pubitemid 36850087)
20. Al Dhaheri RS, Douglas LJ. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob. Agents Chemother. 52, 1884-1887 (2008). (Pubitemid 351614696)
21. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46, 1773-1780 (2002). (Pubitemid 34535196)
22. Mukherjee PK, Long L, Kim HG et al. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheterassociated Candida biofilms. Int. J. Antimicrob. Agents 33, 149-153 (2009).
23. Clancy CJ, Nguyen MH, Clancy CJ et al. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J. Antimicrob. Chemother. 41, 127-130 (1998). (Pubitemid 28064262)
24. Smith D, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30(2), 167-172 (2008). (Pubitemid 351521643)
25. Klepser ME, Wolfe EJ, Jones RN et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41, 1392-1395 (1997). (Pubitemid 27231450)
26. Groll AH, Walsh TJ. Antifungal agents. In:Textbook of Pediatric Infections Diseases (6th Edition). Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds). Saunders Elsevier, PA, USA, 3272-3278, (2009).
27. Andes D, Safdar N, Marchillo K et al. Pharmacokinetic-pharmacodynamic comparison of amphoterici B [AMB] and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50, 674-684 (2006). (Pubitemid 43190982)
28. Lewis RE, Liao G, Hou J et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51, 1253-1258 (2007). (Pubitemid 46586802)
29. Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B [AmBisome] and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46, 828-833 (2002). (Pubitemid 34157670)
30. Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50, 1287-1292 (2006).
31. Hong Y, Shaw PJ, Nath CE et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 50, 935-942 (2006). (Pubitemid 43327797)
32. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33, 1989-1993 (1989). (Pubitemid 19266266)
33. Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182, 274-282 (2000). (Pubitemid 30497814)
34. Groll AH, Lyman CA, Petraitis V et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50, 3418-3423 (2006). (Pubitemid 44527518)
35. Bellmann R, Egger P, Djanani A et al. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int. J. Antimicrob. Agents 23, 80-83 (2004). (Pubitemid 38087961)
36. Nath CE, McLachlan AJ, Shaw PJ et al. Amphotericin B dose optimization in children with malignant diseases. Chemotherapy 53, 142-147 (2007). (Pubitemid 46377223)
37. Wurthwein G, Groll AH, Hempel G et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 49, 5092-5098 (2005). (Pubitemid 41778925)
38. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50, 2009-2015 (2006). (Pubitemid 43807519)
39. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49, 7-10 (2002). (Pubitemid 34162651)
40. Lass-Florl C, Mayr A, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52, 3637-3641 (2008).
41. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med. Mycol. 46, 541-546 (2008).
42. Kovacicova G, Hanzen J, Pisarcikova M et al. Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors. J. Infect. Chemother. 7, 45-48 (2001) . (Pubitemid 32377857)
43. Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin. Infect. Dis. 36, 14-18 (2003).
44. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46, 1581-1582 (2002). (Pubitemid 34415351)
45. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J. Pediatr. Hematol. Oncol. 26, 421-426 (2004). (Pubitemid 39025253)
46. Lucas da Silva PS, Iglesias SB. Hypokalemic rhabdomyolysis in a child due to amphotericin B therapy. Eur. J. Pediatr. 166, 169-171 (2007). (Pubitemid 46025509)
47. Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr. Pulmonol. 33, 497-500 (2002). (Pubitemid 34547872)
48. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27, 820-826 (2008).
49. Wiwanitkit V. Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases. J. Hyperten. 24, 1445 (2006). (Pubitemid 43948346)
50. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12, 463-470 (2000). (Pubitemid 32048160)
51. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch. Intern. Med. 148, 2389-2394 (1988).
52. Alexander BD, Wingard JR, Alexander BD et al. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. 40(Suppl. 6), 414-421 (2005).
53. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex [ABLC] vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma 40, 511-520 (2001). (Pubitemid 32303242)
54. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340, 764-771 (1999). (Pubitemid 29114295)
55. Wingard J, White M, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31, 1155-1163 (2000). (Pubitemid 32295443)
56. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359-366 (2002). Demonstrates the efficiency of amphotericin B in invasive aspergillosis. (Pubitemid 34852563)
57. Fischer MA, Winkelmayer WC, Rubin RH et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin. Infect. Dis. 41, 301-307 (2005). (Pubitemid 41022104)
58. Pappas PG, Kauffman CA, Andes D et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009).
59. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46, 2620-2629 (2008).
60. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115, 4745-4752, (2009).
61. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr. Infect. Dis. J. 28, 1061-1063 (2009).
62. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331, 1325-1330 (1994). (Pubitemid 24347001)
63. Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J. 15, 1107-1112 (1996). (Pubitemid 27014703)
64. Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002). (Pubitemid 35461658)
65. Walsh TJ, Teppler H, Donowitz G et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391-1402 (2004).
66. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123, 877-884 (2009).
67. Kuse ER, Chetchotisakd P, da Cunha CA et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 369, 1519-1527 (2007). (Pubitemid 46670281)
68. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007). (Pubitemid 47580382)
69. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin. Infect. Dis. 40, 384-391 (2005).
70. Walsh TJ, Seibel NL, Arndt C et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr. Infect. Dis. J. 18, 702-708 (1998)
71. Invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27, 820-826 (2008).
72. Wiwanitkit V. Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases. J. Hyperten. 24, 1445 (2006). (Pubitemid 43948346)
73. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12, 463-470 (2000). (Pubitemid 32048160)
74. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch. Intern. Med. 148, 2389-2394 (1988).
75. Alexander BD, Wingard JR, Alexander BD et al. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. 40(Suppl. 6), 414-421 (2005).
76. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex [ABLC] vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma 40, 511-520 (2001). (Pubitemid 32303242)
77. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340, 764-771 (1999). (Pubitemid 29114295)
78. Wingard J, White M, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31, 1155-1163 (2000). (Pubitemid 32295443)
79. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359-366 (2002). Demonstrates the efficiency of amphotericin B in invasive aspergillosis. (Pubitemid 34852563)
80. Fischer MA, Winkelmayer WC, Rubin RH et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin. Infect. Dis. 41, 301-307 (2005). (Pubitemid 41022104)
81. Pappas PG, Kauffman CA, Andes D et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009).
82. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46, 2620-2629 (2008).
83. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115, 4745-4752, (2009).
84. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr. Infect. Dis. J. 28, 1061-1063 (2009).
85. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331, 1325-1330 (1994). (Pubitemid 24347001)
86. Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J. 15, 1107-1112 (1996). (Pubitemid 27014703)
87. Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002). (Pubitemid 35461658)
88. Walsh TJ, Teppler H, Donowitz G et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391-1402 (2004).
89. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123, 877-884 (2009).
90. Kuse ER, Chetchotisakd P, da Cunha CA et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 369, 1519-1527 (2007). (Pubitemid 46670281)
91. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007). (Pubitemid 47580382)
92. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin. Infect. Dis. 40, 384-391 (2005).
93. Walsh TJ, Seibel NL, Arndt C et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr. Infect. Dis. J. 18, 702-708 (1998).
94. Steinbach WJ. Antifungal agents in children. Pediatr. Clin. North Am. 52, 895-915 (2005). (Pubitemid 40733599)
95. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36, 1221-1228 (2003). (Pubitemid 36629929)
96. Herbrecht R, Denning DW, Patterson TF et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002). (Pubitemid 34851833)
97. Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121, 1286-1294 (2008).
98. Walsh TJ, Anaissie EJ, Denning DW et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360 (2008). (Pubitemid 351265310)
99. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party [AGIHO] of the German Society of Hematology and Oncology [DGHO]. Ann. Hematol. 88, 97-110 (2009).
100. Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med. Mycol. 47(Suppl. 1), 387-393 (2009).
101. Kolve H, Ahlke E, Fegeler W, Ritter J, Jürgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J. Antimicrob. Chemother. 64, 383-387 (2009).
102. Moen MD, Lyseng-Willisamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69, 361-392 (2009).
103. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B ipid complex [ABLC] treatment in allogeneic hematopoietic cell transplant [HCT] recipients with invasive aspergillosis [IA]. Bone Marrow Transplant. 36, 873-877 (2005). (Pubitemid 41655613)
104. Bennett JE, Dismukes WE, Duma RJ et al. Comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 30, 126-131 (1979). (Pubitemid 10225854)
105. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337, 15-21 (1997). (Pubitemid 27290842)
106. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47, 123-130 (2008). (Pubitemid 351920599)
107. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B [AmBisome] compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11, 1463-1471 (1997). (Pubitemid 27421177)
108. Baddour LM, Perfect JR, Ostrosky-Zeichner L et al. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin. Infect. Dis. 40(Suppl. 6), 409-413 (2005).
109. Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS Clin. Infect. Dis. 22, 315-321 (1996). (Pubitemid 26056161)
110. Singh N, Dromer F, Perfect JR et al. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin. Infect. Dis. 47, 1321-1327 (2008).
111. Almyroudis NG, Sutton DA, Linden P et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am. J. Transplant. 6, 2365-2374 (2006). (Pubitemid 44359422)
112. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Micro. Infect. Dis. 25, 215-229 (2006). (Pubitemid 43800540)
113. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41, 634-653 (2005). (Pubitemid 41170352)
114. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 40, 401-408 (2005).
115. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin. Microbiol. Rev. 20, 115-132 (2007). (Pubitemid 46167770)
116. Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137, 105-109 (2002). (Pubitemid 34779154)
117. Jorgensen KJ, Gotzsche PC, Johansen HK et al. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst. Rev. (1), CD004707 (2006).
118. Johansen HK, Gotzsche PC, Johansen HK et al. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst. Rev. (2), CD000239 (2002).
119. Malik IA, Moid I, Aziz Z et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am. J. Med. 105, 478-483 (1998). (Pubitemid 29013332)
120. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31, 1155-1163 (2000). (Pubitemid 32295443)
121. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98, 711-718 (1997). (Pubitemid 27386554)